Federica started working in the MacLaren group in September 2018, where she had a key role in the choroideremia gene therapy programme in taking responsibility for the vector potency assay which is used to validate the efficacy of each vector batch as it is manufactured. She then progressed to become an MSc student in October 2019. Prior to joining the group, she obtained a bachelor’s degree in neuroscience at Queen Mary University of London, in 2018.
Recently she transferred from the MSc programme to the DPhil programme, and she is currently working towards a DPhil in Clinical Neuroscience under the supervision of Professor Robert MacLaren. Her project focuses on the development of a minicircle gene therapy system for expanding treatment options of inherited retinal diseases.
During the initial global outbreak of the COVID-19 pandemic, Federica returned to Milan and helped with COVID-19 research from April to July 2020 in the Laboratory of Microbiology and Virology, Sacco University Hospital in Milan.